Risk assessment of careHPV testing for the detection of cervical precancerous lesions: 5-year follow-up of a screening program in China
Journal of Infection and Public Health · 2025
DOI: 10.1016/j.jiph.2024.102611 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Infection and Public Health, 2025. Verfasst von Sumeng Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Col…. Hauptthemen laut MEDLINE: Papillomavirus Infections, Uterine Cervical Neoplasms, Early Detection of Cancer. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chinese Academy of Medical Sciences and Peking Union Medical College.
Abstract (Originalsprache)
BACKGROUND: CareHPV is a highly promising screening HPV assay that functions as a simplified and rapid point-of-care test, making it particularly well-suited for low-resource areas. It exhibits high sensitivity for detecting cervical precancerous lesions in cross-sectional study design. However, there is still limited evidence on the long-term protection of careHPV testing in the practical setting. METHODS: A government-led cervical cancer screening program was implemented in Ordos City, China, specifically targeting female residents aged 35-64 years since 2016. CareHPV specimens were collected and visual inspection with acetic acid and Lugol iodine (VIA/VILI) was performed in the baseline screening. Women who were HPV-positive or VIA/VILI-suspected cancer at baseline were invited for a one-year follow-up screening. At the same time, those who were HPV-negative were scheduled for a 5-year rescreening. Women diagnosed with cervical intra-epithelial neoplasia grade 2 or worse (CIN2+) would be referred to clinical treatment as per the clinical guidelines. The current study includes participants who had valid baseline screening results and attended follow-ups with valid careHPV results conducted between January 2017 and December 2021, aiming to assess the long-term risk stratification for careHPV. Cumulative incidence rate (CIRs) and hazard ratio (HRs) for CIN2+ were calculated, using survival analysis. RESULTS: Among the 179,306 women enrolled in the baseline screening between 2016 and 2020, 12.60 % tested positive for careHPV, with 657 cases of CIN2+ identified. The final analysis included 18,562 women in our study, of whom 58.54 % were careHPV-positive at baseline. The final analysis consisted of 17,905 women who underwent screening between 2016 and 2020 and attended follow-ups from 2017 to 2021, with valid HPV results, and 657 women who identified as CIN2+ at the baseline. The 5-year CIRs were 0.003 and 0.101 among women who tested negative and positive for baseline careHPV, respectively. The 5-year CIRs for developing CIN2+ during follow-ups were 0.009, 0.009, and 0.11 for the groups of women who transitioned from careHPV-negative to positive (831, 4.64 %), careHPV-positive to negative (6688, 37.35 %), and maintained a stable positive careHPV status (3535, 19.74 %), respectively. CONCLUSIONS: Our findings support the long-term safety and protection of careHPV testing in 5-year follow-ups of screening programs. CareHPV represents a viable option for regions with limited healthcare resources.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Outpatient Department, Peking University…
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences/ Peking Union Medical College, Beijing 100730, China.
- Center for Global Health, School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing 100730, China.
- Ordos Maternal and Child Health Care Hospital, Inner Mongolia Autonomous Region, Ordos 017010, China.
- Ijin Holo Banner Maternal and Child Care Centre of Ordos, Inner Mongolia Autonomous Region, Ordos 017200, China.
Förderung
- Chinese Academy of Medical Sciences and Peking Union Medical College
Zitieren
APA
Wang, S., Dang, L., Yin, J., Duan, X., Liu, D., Feng, H., Zhang, L., Su, M., Jia, D., Yan, C., Liu, M., Cao, X., Sun, M., Qiao, Y., & Zhao, F. (2025). Risk assessment of careHPV testing for the detection of cervical precancerous lesions: 5-year follow-up of a screening program in China. Journal of Infection and Public Health. https://doi.org/10.1016/j.jiph.2024.102611
Vancouver
Wang S, Dang L, Yin J, Duan X, Liu D, Feng H, et al. Risk assessment of careHPV testing for the detection of cervical precancerous lesions: 5-year follow-up of a screening program in China. Journal of Infection and Public Health. 2025. doi:10.1016/j.jiph.2024.102611
BibTeX
@article{Wang2025,
author = {Wang, Sumeng and Dang, Le and Yin, Jian and Duan, Xianzhi and Liu, Duoli and Feng, Hui and Zhang, Lifeng and Su, Meili and Jia, Dongbin and Yan, Cailing and Liu, Meili and Cao, Xiaoyan and Sun, Min and Qiao, Youlin and Zhao, Fanghui},
title = {Risk assessment of careHPV testing for the detection of cervical precancerous lesions: 5-year follow-up of a screening program in China},
journal = {Journal of Infection and Public Health},
year = {2025},
doi = {10.1016/j.jiph.2024.102611}
}
EUVIMED